Abstract
Processing of information by the central nervous system (CNS) depends on the dendritic morphology of postsynaptic neurons. The patterning of dendrites is determined by extrinsic and intrinsic factors that promote the activation of cellular signaling pathways. These factors and signaling cascades may lead to the transcriptional activation of regulators of neuronal morphology. Interestingly, when there is an abnormal decrease in the number of dendrite branches and disruption of proper networks, neurodegenerative diseases, including Rett Syndrome, autism, and mental retardation, may result. In this review, we evaluate the potential of regulators of dendrite patterning as targets for drug design for the treatment of neurodegenerative diseases and altered neuronal growth in the CNS. Particular attention is directed towards a specific regulator of dendrite branching reported by our group, cypin (cytosolic PSD-95 interactor). We discuss this novel intrinsic regulator of dendrite branching as an innovative pharmacological target for the use of computer-aided rational drug design to control guanine levels, microtubule assembly, and neuronal differentiation during CNS development and in disease states.
Keywords: Dendrite branching, dendrite development, signaling pathways, transcriptional regulation, neurotrophins, cypin, guanine deaminase, neurological disorders
Central Nervous System Agents in Medicinal Chemistry
Title: Novel Pharmacological Targets for Controlling Dendrite Branching and Growth During Neuronal Development
Volume: 8 Issue: 2
Author(s): Jose R. Fernandez and Bonnie L. Firestein
Affiliation:
Keywords: Dendrite branching, dendrite development, signaling pathways, transcriptional regulation, neurotrophins, cypin, guanine deaminase, neurological disorders
Abstract: Processing of information by the central nervous system (CNS) depends on the dendritic morphology of postsynaptic neurons. The patterning of dendrites is determined by extrinsic and intrinsic factors that promote the activation of cellular signaling pathways. These factors and signaling cascades may lead to the transcriptional activation of regulators of neuronal morphology. Interestingly, when there is an abnormal decrease in the number of dendrite branches and disruption of proper networks, neurodegenerative diseases, including Rett Syndrome, autism, and mental retardation, may result. In this review, we evaluate the potential of regulators of dendrite patterning as targets for drug design for the treatment of neurodegenerative diseases and altered neuronal growth in the CNS. Particular attention is directed towards a specific regulator of dendrite branching reported by our group, cypin (cytosolic PSD-95 interactor). We discuss this novel intrinsic regulator of dendrite branching as an innovative pharmacological target for the use of computer-aided rational drug design to control guanine levels, microtubule assembly, and neuronal differentiation during CNS development and in disease states.
Export Options
About this article
Cite this article as:
Fernandez R. Jose and Firestein L. Bonnie, Novel Pharmacological Targets for Controlling Dendrite Branching and Growth During Neuronal Development, Central Nervous System Agents in Medicinal Chemistry 2008; 8 (2) . https://dx.doi.org/10.2174/187152408784533923
DOI https://dx.doi.org/10.2174/187152408784533923 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Impact of Natural Compounds on the Treatment of Neurodegenerative Diseases
Current Organic Chemistry Humanin Peptide Binds to Insulin-Like Growth Factor-Binding Protein 3 (IGFBP3) and Regulates Its Interaction with Importin-β
Protein & Peptide Letters Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Current Alzheimer Research Stem Cell-Mediated Gene Delivering for the Treatment of Cerebral Ischemia: Progress and Prospectives
Current Drug Targets Role of Ligand-Based Drug Design Methodologies toward the Discovery of New Anti- Alzheimer Agents: Futures Perspectives in Fragment-Based Ligand Design
Current Medicinal Chemistry Systemic and CNS Inflammation Crosstalk: Implications for Alzheimer’s Disease
Current Alzheimer Research Phenylbutyrate is a Multifaceted Drug that Exerts Neuroprotective Effects and Reverses the Alzheimer´s Disease-like Phenotype of a Commonly Used Mouse Model
Current Pharmaceutical Design Cofilin/Actin Rod Formation by Dysregulation of Cofilin-1 Activity as a Central Initial Step in Neurodegeneration
Mini-Reviews in Medicinal Chemistry Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry How Immune-inflammatory Processes Link CNS and Psychiatric Disorders: Classification and Treatment Implications
CNS & Neurological Disorders - Drug Targets Hypothalamic Insulin-Sensitizing Effect of Exenatide in Dietary Induced Rat Model of Obesity
Current Drug Therapy Recent updates on the dynamic association between oxidative stress and neurodegenerative disorders
CNS & Neurological Disorders - Drug Targets Therapeutic Approaches to Modulating Glutathione Levels as a Pharmacological Strategy in Alzheimer`s Disease
Current Alzheimer Research Therapeutic Approaches for Lysosomal Storage Diseases: A Patent Update
Recent Patents on CNS Drug Discovery (Discontinued) Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry Provoking Neuroprotection by Peroxynitrite
Current Pharmaceutical Design Elevated Homocysteine Levels in Parkinsons Disease: Is there Anything Besides L-Dopa Treatment?
Current Medicinal Chemistry The Development of Cannabinoid CBII Receptor Agonists for the Treatment of Central Neuropathies
Central Nervous System Agents in Medicinal Chemistry Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors
Current Pharmaceutical Design Epigenetic Mechanisms in Alzheimer's Disease
Current Medicinal Chemistry